Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:GNFT NASDAQ:NAGE NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$19.71+3.6%$19.95$15.47▼$36.37$799.64M1.17261,833 shs297,391 shsGNFTGENFIT$4.20+0.3%$3.94$2.55▼$6.42$210.05M1.168,207 shs3,470 shsNAGENiagen Bioscience$9.61-0.1%$10.08$3.18▼$14.69$766.43M2.21939,333 shs851,361 shsTSHATaysha Gene Therapies$3.07-5.2%$2.80$1.05▼$3.40$837.50M0.982.97 million shs4.42 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+0.79%-2.56%+12.21%-18.26%-25.00%GNFTGENFIT+1.19%+7.14%+10.40%+2.05%+0.34%NAGENiagen Bioscience+0.21%+3.22%-6.24%-29.42%+188.89%TSHATaysha Gene Therapies-0.31%-0.61%+11.34%+27.56%+39.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$19.71+3.6%$19.95$15.47▼$36.37$799.64M1.17261,833 shs297,391 shsGNFTGENFIT$4.20+0.3%$3.94$2.55▼$6.42$210.05M1.168,207 shs3,470 shsNAGENiagen Bioscience$9.61-0.1%$10.08$3.18▼$14.69$766.43M2.21939,333 shs851,361 shsTSHATaysha Gene Therapies$3.07-5.2%$2.80$1.05▼$3.40$837.50M0.982.97 million shs4.42 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+0.79%-2.56%+12.21%-18.26%-25.00%GNFTGENFIT+1.19%+7.14%+10.40%+2.05%+0.34%NAGENiagen Bioscience+0.21%+3.22%-6.24%-29.42%+188.89%TSHATaysha Gene Therapies-0.31%-0.61%+11.34%+27.56%+39.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.00Buy$39.1498.59% UpsideGNFTGENFIT 3.00Buy$9.00114.23% UpsideNAGENiagen Bioscience 3.00Buy$13.4239.65% UpsideTSHATaysha Gene Therapies 3.00Buy$8.29169.89% UpsideCurrent Analyst Ratings BreakdownLatest GNFT, TSHA, NAGE, and AVBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/19/2025GNFTGENFITHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.008/18/2025AVBPArriVent BioPharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025TSHATaysha Gene TherapiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.50 ➝ $8.008/12/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $42.008/12/2025AVBPArriVent BioPharmaCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $33.008/12/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.008/11/2025NAGENiagen BioscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $12.007/22/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.007/11/2025TSHATaysha Gene TherapiesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/10/2025AVBPArriVent BioPharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$33.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$7.65 per shareN/AGNFTGENFIT$76.77M2.74$0.07 per share59.17$1.50 per share2.80NAGENiagen Bioscience$116.30M6.59$0.06 per share162.30$0.60 per share16.02TSHATaysha Gene Therapies$8.33M100.54N/AN/A$0.35 per share8.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$80.49M-$4.02N/AN/AN/AN/A-55.40%-51.97%11/13/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A9/22/2025 (Estimated)NAGENiagen Bioscience$8.55M$0.2145.76∞N/A15.24%23.12%15.53%N/ATSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest GNFT, TSHA, NAGE, and AVBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/11/2025Q2 2025AVBPArriVent BioPharma-$0.70-$0.90-$0.20-$0.90N/AN/A8/6/2025Q2 2025NAGENiagen Bioscience$0.02$0.04+$0.02$0.04$28.55 million$31.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A12.7412.74GNFTGENFIT0.081.231.23NAGENiagen BioscienceN/A3.883.24TSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%GNFTGENFIT2.24%NAGENiagen Bioscience15.41%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma18.58%GNFTGENFIT4.20%NAGENiagen Bioscience9.39%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4040.57 million33.03 millionN/AGNFTGENFIT12050.00 million47.90 millionNot OptionableNAGENiagen Bioscience12079.75 million72.26 millionN/ATSHATaysha Gene Therapies180272.80 million262.48 millionOptionableGNFT, TSHA, NAGE, and AVBP HeadlinesRecent News About These CompaniesTaysha Gene Therapies, Inc. $TSHA Shares Acquired by Octagon Capital Advisors LPSeptember 11 at 6:03 AM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Sets New 52-Week High - Here's WhySeptember 7, 2025 | americanbankingnews.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.29 Consensus PT from AnalystsSeptember 5, 2025 | americanbankingnews.comTaysha Gene Therapies, Inc. $TSHA Stake Increased by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Purchases 608,200 Shares of Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comNuveen LLC Acquires New Stake in Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comTaysha Gene Therapies, Inc.September 3, 2025 | edition.cnn.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Buy" from BrokeragesSeptember 3, 2025 | marketbeat.comPiper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9August 25, 2025 | msn.comKovitz Investment Group Partners LLC Invests $407,000 in Taysha Gene Therapies, Inc. $TSHAAugust 24, 2025 | marketbeat.comFY2025 Earnings Forecast for TSHA Issued By Chardan CapitalAugust 19, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Forecast for TSHA EarningsAugust 17, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst UpgradeAugust 15, 2025 | marketbeat.comWells Fargo & Company Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00August 15, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $10.00August 14, 2025 | marketbeat.comTaysha Gene Therapies price target raised to $14 from $11 at CanaccordAugust 13, 2025 | msn.com4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...August 13, 2025 | benzinga.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Earnings ResultsAugust 13, 2025 | marketbeat.comTaysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...August 13, 2025 | finance.yahoo.comXTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)August 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Buffett’s Cash Hoard Signals Market Caution, Value Plays EmergeBy Gabriel Osorio-Mazilli | August 19, 2025Why Sprouts Farmers Market is Buying $1 Billion of Its Own StockBy Gabriel Osorio-Mazilli | August 25, 2025Brinker Serves Up Earnings Beat, Sidesteps Cost PressuresBy Chris Markoch | August 14, 2025GNFT, TSHA, NAGE, and AVBP Company DescriptionsArriVent BioPharma NASDAQ:AVBP$19.71 +0.69 (+3.63%) Closing price 04:00 PM EasternExtended Trading$19.71 0.00 (0.00%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.GENFIT NASDAQ:GNFT$4.20 +0.01 (+0.24%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Niagen Bioscience NASDAQ:NAGE$9.61 -0.01 (-0.10%) As of 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Taysha Gene Therapies NASDAQ:TSHA$3.07 -0.17 (-5.25%) Closing price 04:00 PM EasternExtended Trading$3.10 +0.04 (+1.14%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
